HCPCS Code for Patients with metastatic nsclc with epidermal growth factor receptor (egfr) mutations, alk genomic tumor aberrations, or other targetable genomic abnormalities with approved first-line targeted therapy, such as nsclc with ros1 rearrangement, braf v600e mutation, ntrk 1/2/3 gene fusion, met ex14 skipping mutation, and ret rearrangement M1412
HCPCS code M1412 for Patients with metastatic nsclc with epidermal growth factor receptor (egfr) mutations, alk genomic tumor aberrations, or other targetable genomic abnormalities with approved first-line targeted therapy, such as nsclc with ros1 rearrangement, braf v600e mutation, ntrk 1/2/3 gene fusion, met ex14 skipping mutation, and ret rearrangement as maintained by CMS falls under Other Services.
Subscribe to Codify by ÐÇ¿ÕÈë¿Úand get the code details in a flash.
Patients with metastatic nsclc with epidermal growth factor receptor (egfr) mutations, alk genomic tumor aberrations, or other targetable genomic abnormalities with approved first-line targeted therapy, such as nsclc with ros1 rearrangement, braf v600e mutation, ntrk 1/2/3 gene fusion, met ex14 skipping mutation, and ret rearrangement
Tabs
Match supply and drug codes in a snap. View corresponding CPT® codes and their definitions.
Tabs
Subscribers see the ICD-10-CM codes a contractor allows and full LCD policy text on the same website.
Protect Part B Payments by complying with Correct Coding Initiative (CCI) edits. Subscribers see the full list of column 2 codes for the searched HCPCS code.
Read a HCPCS Coding Clinic® article by subscribing today.